The estimated Net Worth of Vito J. Palombella is at least $1.57 Millón dollars as of 3 August 2022. Vito Palombella owns over 4,463 units of Surface Oncology Inc stock worth over $93,317 and over the last 14 years he sold SURF stock worth over $670,687. In addition, he makes $810,510 as Chief Scientific Officer at Surface Oncology Inc.
Sign up
Vito Palombella SURF stock SEC Form 4 insiders trading
Vito has made over 12 trades of the Surface Oncology Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 4,463 units of SURF stock worth $7,676 on 3 August 2022.
The largest trade he's ever made was selling 26,325 units of Surface Oncology Inc stock on 21 July 2021 worth over $160,583. On average, Vito trades about 4,064 units every 145 days since 2011. As of 3 August 2022 he still owns at least 87,212 units of Surface Oncology Inc stock.
You can see the complete history of Vito Palombella stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Vito Palombella biography
Dr. Vito J. Palombella Ph.D. serves as Chief Scientific Officer of the Company. Prior to joining us, Dr. Palombella served in a variety of roles at Infinity Pharmaceuticals, Inc. from January 2004 to January 2016, most recently as Chief Scientific Officer. Prior to that, he was Director of Molecular Biology and Protein Chemistry at Syntonix Pharmaceuticals, Inc. (now Biogen Inc.) from October 2000 to January 2004, Senior Director of Cell and Molecular Biology at Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Co. Ltd.) from December 1999 to October 2000, Senior Director of Cell and Molecular Biology at LeukoSite, Inc. from July 1999 to December 1999, and held a number of positions at ProScript, Inc. from September 1994 to July 1999. Dr. Palombella received a B.S. in Microbiology from Rutgers University and an M.S. and Ph.D. in Viral Oncology and Immunology from the New York University Medical Center and completed his post-doctoral training at Harvard University.
What is the salary of Vito Palombella?
As the Chief Scientific Officer of Surface Oncology Inc, the total compensation of Vito Palombella at Surface Oncology Inc is $810,510. There are 1 executives at Surface Oncology Inc getting paid more, with J. Jeffrey Goater having the highest compensation of $1,642,260.
How old is Vito Palombella?
Vito Palombella is 57, he's been the Chief Scientific Officer of Surface Oncology Inc since 2016. There are 3 older and 13 younger executives at Surface Oncology Inc. The oldest executive at Surface Oncology Inc is Elliott Sigal, 68, who is the Independent Director.
What's Vito Palombella's mailing address?
Vito's mailing address filed with the SEC is C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE, MA, 02139.
Insiders trading at Surface Oncology Inc
Over the last 7 years, insiders at Surface Oncology Inc have traded over $69,198,912 worth of Surface Oncology Inc stock and bought 2,836,996 units worth $42,496,090 . The most active insiders traders include Forest Baskett, Scott D Sandell y Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of $156,856. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth $6,619.
What does Surface Oncology Inc do?
surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww
What does Surface Oncology Inc's logo look like?
Complete history of Vito Palombella stock trades at Infinity Pharmaceuticals y Surface Oncology Inc
Surface Oncology Inc executives and stock owners
Surface Oncology Inc executives and other stock owners filed with the SEC include:
-
J. Jeffrey Goater,
President, Chief Executive Officer, Director -
Vito Palombella,
Chief Scientific Officer -
Robert Ross,
Chief Medical Officer -
J. Jeffrey Goater,
CEO, Pres & Director -
Dr. Robert W. Ross,
Chief Medical Officer -
Daniel Lynch,
Executive Chairman of the Board -
Laurie Stelzer,
Independent Director -
Cameron McDonough,
Independent Director -
Armen Shanafelt,
Independent Director -
David Grayzel,
Independent Director -
Elliott Sigal,
Independent Director -
Ramy Ibrahim,
Independent Director -
Liisa Nogelo,
Chief Legal Officer, Secretary -
Wendy Dwyer,
Chief Business Officer -
Jessica Fees,
Principal Financial Officer, Principal Accounting Officer, Senior Vice President, Finance and Treasurer -
Alison O'Neill,
Sr. VP of Clinical Devel. -
Bob Steininger,
Sr. VP of Chemistry, Manufacturing & Controls -
Lisa McGrath,
Sr. VP of HR -
Liisa I. Nogelo,
Sec., Chief Compliance Officer & Chief Legal Officer -
Jessica Fees,
Sr. VP of Fin. & Treasurer -
Carsten Brunn,
Director -
Theresa Boni,
General Counsel & Secretary -
Enterprise Associates 14, L...,
-
Ravi Viswanathan,
10% owner -
Scott D Sandell,
10% owner -
Patrick J Kerins,
10% owner -
Forest Baskett,
10% owner -
M James Barrett,
10% owner -
Institutes For Bio Medical ...,
-
Venture Fund Ix, L.P.Atlas ...,
-
Management Group, Llc Lilly...,
-
Peter W. Sonsini,
10% owner -
David M Mott,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Peter J Barris,
10% owner -
Enterprise Associates 14, L...,
10% owner -
2017 Liquidating Trust Kear...,
-
Llc Fmr,
-
Ltd Fil,
-
Geoff Mcdonough,
Director -
Capital, Llc Eco R1,
10% owner -
Alison Oneill,
Chief Medical Officer -
Henry C. Rath,
Chief Business Officer -
Denice Torres,
Director -
Benjamin Hickey,
Director -
Chandra Adams,
Deputy GC